Consensus Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-09-22 EDT			After hours 18:42:10
182.56 ^USD	+5.56%		182.68	+0.07%

09-21	Health Care Up on Drug Breakthrough Hopes - Health Care Roundup	DJ
09-21	Moderna Provides Details on Data Presentations at Upcoming Conferences	MT

Evolution of the Average Target: Moderna, Inc.

Evolution of the Target Price: Moderna, Inc.

Changes in Analyst Recommendations: Moderna, Inc.

c9b9ddd6241d997eb0754cda23f986c4._wE5DlaZ2Yelf9i2XlP8yWAqbLKy0X6pK4wCXUzi1GY.lTZmbCOgn7TCTY_QGQSKhDAZHsiLvhSaYdtbOXSGogXOQ3B6D8a36v0RlQ~633740effe27d01907b80a7d19088ef4

Analysts' recommendations: Moderna, Inc.

09-11	Berenberg Boosts Price Target on Moderna to $100 From $45, Keeps Hold Rating	MT
09-09	Moderna Set for 3 Near-Term INT Data Readouts, UBS Says	MT
09-03	Evercore ISI Adjusts Moderna Price Target to $80 From $50, Maintains In Line Rating	MT
09-03	Wall Street's Triple Squeeze
09-03	Rothschild & Co Redburn Downgrades Moderna to Sell From Neutral, Adjusts PT to $81 From $40	MT
09-03	Analyst recommendations: Copart, Moderna, Broadcom, DuPont de Nemours…
08-28	Argus Research Upgrades Moderna to Buy From Hold, $180 Price Target	MT
08-26	U.S. research roundup- Intuit, MongoDB, Zscaler	RE
08-26	Deutsche Bank Adjusts Moderna Price Target to $125 From $45, Maintains Hold Rating	MT
08-25	Moderna Shares Rise After Wolfe Research Upgrade	MT
08-25	Wolfe Upgrades Moderna to Peer Perform From Underperform	MT
08-24	Barclays Adjusts Price Target on Moderna to $125 From $48	MT
08-24	Analyst recommendations: Kimberly-Clark, Palantir, Snap, Crowdstrike, Accenture…
08-21	JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating	MT
08-21	Analyst recommendations: Equifax, Medpace Holdings, Applied Materials, PayPal, Moderna…
08-20	UBS Adjusts Moderna Price Target to $150 From $50, Maintains Neutral Rating	MT
08-20	Jefferies Adjusts Price Target on Moderna to $150 From $60, Keeps Hold Rating	MT
08-20	Piper Sandler Adjusts Price Target on Moderna to $167 From $77, Keeps Overweight Rating	MT
08-20	Analyst recommendations: Datadog, Merck, Estee Lauder, Moderna, Target…
08-19	Piper Sandler Adjusts Price Target on Moderna to $167 From $77, Maintains Overweight Rating	MT
08-19	BofA Securities Upgrades Moderna to Neutral From Underperform Following Intismeran 'Success', Raises Price Target to $170 From $40	MT
08-19	Goldman Sachs Adjusts Price Target on Moderna to $120 From $67, Keeps Neutral Rating	MT
08-19	Moderna and Merck & Co, the day's Wall Street standouts
08-19	William Blair Upgrades Moderna to Outperform From Market Perform	MT
08-03	Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MODERNA, INC.					-30.87%
	REGENERON PHARMACEUTICALS, INC.					+6.41%
	CSL LIMITED					-0.57%
	SAMSUNG BIOLOGICS CO.,LTD.					+40.7%
	UCB					+34.37%
	BIOGEN INC.					+8.72%
	INCYTE CORPORATION					+2.48%
	INNOVENT BIOLOGICS, INC.					+26.42%
	SWEDISH ORPHAN BIOVITRUM AB					+12.92%
	BRIDGEBIO PHARMA, INC.					+63.86%
	Average					+16.44%
	Weighted average by Cap.					+9.31%